Cargando…

Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns

Androgen deprivation therapy (ADT) is a standard treatment for prostate cancer patients, routinely used in the palliative or in the curative setting in association with radiotherapy. Among the systemic long-term side effects of ADT, growing data suggest a potentially increased risk of dementia/Alzhe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Achard, Vérane, Ceyzériat, Kelly, Tournier, Benjamin B., Frisoni, Giovanni B., Garibotto, Valentina, Zilli, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712866/ https://www.ncbi.nlm.nih.gov/pubmed/34970480 http://dx.doi.org/10.3389/fonc.2021.734881

Ejemplares similares

In Vivo TSPO Signal and Neuroinflammation in Alzheimer’s Disease
por: Tournier, Benjamin B., et al.
Publicado: (2020)

Low-dose brain irradiation normalizes TSPO and CLUSTERIN levels and promotes the non-amyloidogenic pathway in pre-symptomatic TgF344-AD rats
por: Ceyzériat, Kelly, et al.
Publicado: (2022)

PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions
por: le Guevelou, Jennifer, et al.
Publicado: (2021)

Letter from Switzerland
por: Achard, Vérane, et al.
Publicado: (2020)

Urinary toxicity after salvage re-irradiation for prostate cancer local failure after definitive radiotherapy: a clinical and dosimetric prognostic factors analysis
por: Dipasquale, Giovanna, et al.
Publicado: (2022)

Dopaminergic dysfunction in the 3xTg-AD mice model of Alzheimer’s disease
por: Gloria, Yesica, et al.
Publicado: (2021)

18 kDa Translocator Protein TSPO Is a Mediator of Astrocyte Reactivity
por: Tournier, Benjamin B., et al.
Publicado: (2023)

Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial
por: Lorton, Orane, et al.
Publicado: (2023)

Reactive astrocytes mediate TSPO overexpression in response to sustained CNTF exposure in the rat striatum
por: Ceyzériat, Kelly, et al.
Publicado: (2023)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

How To Manage T3b Prostate Cancer in the Contemporary Era: The Benefits of Surgery
por: Peyrottes, Arthur, et al.
Publicado: (2023)

How To Manage T3b Prostate Cancer in the Contemporary Era: Is Radiotherapy the Standard of Care?
por: Achard, Vérane, et al.
Publicado: (2023)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey
por: Caprioglio, Camilla, et al.
Publicado: (2022)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Astrocytic TSPO Upregulation Appears Before Microglial TSPO in Alzheimer’s Disease
por: Tournier, Benjamin B., et al.
Publicado: (2020)

Alterations in dopamine system and in its connectivity with serotonin in a rat model of Alzheimer’s disease
por: Ceyzériat, Kelly, et al.
Publicado: (2021)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?
por: Patrikidou, Anna, et al.
Publicado: (2021)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023)

Androgen Deprivation Therapy in Patients with Prostate Cancer is Associated with the Risk of Subsequent Alzheimer's Disease but Not with Vascular Dementia
por: Kim, Jong Won, et al.
Publicado: (2022)

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

Influence of age on androgen deprivation therapy-associated Alzheimer’s disease
por: Nead, Kevin T., et al.
Publicado: (2016)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

Amyloid and Tau Induce Cell Death Independently of TSPO Polymerization and Density Changes
por: Tournier, Benjamin B., et al.
Publicado: (2021)

Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer
por: Shahinian, Vahakn B, et al.
Publicado: (2015)

Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells
por: Levina, Elina, et al.
Publicado: (2015)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Transcription Factors Involved in Prostate Gland Adaptation to Androgen Deprivation
por: Rosa-Ribeiro, Rafaela, et al.
Publicado: (2014)

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
por: Shaw, Greg L., et al.
Publicado: (2016)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_an0mngd3fn3m7ol7b0sqodlsf1